A cloud-based precision dosing platform integrates patient-specific data, PK/PD models, and Bayesian forecasting to comprehend each client's medical, pharmacological profile and guide treatment decisions.
FREMONT, CA: InsightRX is a digital healthcare firm that has created a cloud-based solution for precision medicine and clinical analytics that allows doctors to tailor treatment at the point - of - care. Meanwhile, to comprehend each patient's unique profile, the platform uses patient-specific data, pharmacology models, machine learning and effortlessly incorporated into a clinical workflow.
Sentara Healthcare, not-for-profit healthcare representing Virginia and northeastern North Carolina, has integrated InsightRX's precision dosing platform into its electronic health records (EHR) system. According to InsightRX, which provides a cloud-based precision dosing platform to help guide treatment decisions.
Approximately two months after its commercial deal signed, the InsightRX platform went public in Sentara's Epic EHR in January. Sentara wanted to use InsightRX's solution to help individualize vancomycin doses for individual patients to improve safety and follow the 2020 IDSA/PIDS/SHEA vancomycin dosing standards.
"We recognized a need for a system-wide process to address the new recommendations for vancomycin dosing and ensure patient safety while supporting our care team," said Tim Jennings, PharmD, Vice President, and Chief Pharmacy Officer at Sentara. "We needed a tool that was easy to integrate and use in our EHR. This ensures not only an efficient process, but a clinically sound and safe one."
Antibiotic vancomycin helps treat infections caused by bacteria. Inadequate dosages can also be ineffective and develop resistance, while excessive dosages can result in acute renal injury (AKIs). According to a recent literature study published in the Journal of Pharmacy Practice, AKIs affect over 500,000 patients in the US each year and incur 9,400 dollars to 81,000 dollars in additional per-patient hospital expenses.
Sentara could be treating 1,000 to 1,500 hospitalized patients for infections at any given moment, thanks to its 12 facilities. Sentara will provide intravenous vancomycin to 23,000 patients in 2020, totaling around 86,500 doses.
However, to evaluate a patient's unique pharmacological profiles and guide treatment decisions, the cloud-based InsightRX Nova precision dosing platform employs patient-specific data, pharmacokinetic/pharmacodynamic (PK/PD) models and Bayesian prediction.
"InsightRX is proud to support Sentara in providing quality care for patients through the use of precision dosing tools," said Sirj Goswami, Ph.D., CEO, and Co-Founder of InsightRX. "We look forward to a long and successful partnership."
